Table 1.
Response rate (RR) and progression-free survival (PFS) in patients with normal and elevated serum lactate dehydrogenase (LDH) in patients treated in CheckMate 066, 067, 069 studies
Nivolumab + ipilimumab | Nivolumab | Ipilimumab | |
---|---|---|---|
RR LDH ≤ ULN LDH > ULN LDH > 2 × ULN |
65% 45% 33% |
51% 31% 17% |
23% 10% 0% |
PFS LDH ≤ ULN LDH > ULN LDH > 2 × ULN |
NR 5.2 months 2.6 months |
11.3 months 2.7 months 2.1 months |
4.1 months 2.6 months 2.3 months |